Omnicell Files 8-K for Regulatory Disclosure

Ticker: OMCL · Form: 8-K · Filed: Dec 8, 2025 · CIK: 926326

Omnicell, Inc. 8-K Filing Summary
FieldDetail
CompanyOmnicell, Inc. (OMCL)
Form Type8-K
Filed DateDec 8, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, disclosure

Related Tickers: OMCL

TL;DR

Omnicell filed a routine 8-K on 12/8/25 for disclosures, no major news.

AI Summary

Omnicell, Inc. filed an 8-K on December 8, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Omnicell is adhering to its reporting obligations with the SEC, providing transparency to investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for regulatory disclosures and does not appear to contain any new material information that would immediately impact risk.

Key Players & Entities

  • OMNICELL, INC. (company) — Registrant
  • December 8, 2025 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is December 8, 2025.

What is Omnicell, Inc.'s state of incorporation?

Omnicell, Inc. is incorporated in Delaware.

What is Omnicell, Inc.'s IRS Employer Identification Number?

Omnicell, Inc.'s IRS Employer Identification Number is 94-3166458.

What is the principal executive office address for Omnicell, Inc.?

The principal executive office address for Omnicell, Inc. is 4220 North Freeway, Fort Worth, TX 76137.

Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-12-08 08:18:56

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value OMCL NASDAQ Global Select M

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 8, 2025, Omnicell, Inc. (the "Company") issued a press release announcing the launch of Omnicell Titan XT, its next generation, automated dispensing system designed to empower autonomous medication management. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Document 99.1 Press release entitled "Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management" dated December 8, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. OMNICELL, INC. Date: December 8, 2025 /s/ H. Baird Radford, III H. Baird Radford, III Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.